Logotype for Invivyd Inc

Invivyd (IVVD) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Invivyd Inc

Q3 2026 earnings summary

16 Nov, 2026

Executive summary

  • PEMGARDA Q3 revenue was $15.449M, up 18% from $13.129M, while net loss widened to $33.468M from $10.470M as R&D and SG&A increased.

  • Cash and cash equivalents were $126.398M at September 30, 2026; without future external financing, available cash is not expected to fund operations and capital needs beyond one year, raising substantial doubt about going concern.

  • VYD2311 advanced in Phase 3 and Phase 2 programs; DECLARATION interim data and a regulatory update were expected in Q4 2026 following FDA dialogue on the accelerated approval approach.

Financial highlights

  • Q3 product revenue was $15.449M vs. $13.129M YoY; nine-month revenue was $43.478M vs. $36.219M, driven by higher PEMGARDA demand.

  • Q3 R&D expense rose to $18.7M from $8.0M and SG&A to $30.3M from $15.0M, primarily reflecting increased clinical and commercial activity.

  • Q3 operating loss was $34.679M vs. $11.023M; nine-month operating loss was $123.635M vs. $43.005M.

  • Nine-month operating expenses rose to $167.113M from $79.224M, led by R&D of $78.834M and SG&A of $84.931M.

  • Nine-month net loss was $119.261M vs. $41.419M; Q3 and nine-month loss per share were $0.10 vs. $0.06 and $0.38 vs. $0.30, respectively.

Outlook and guidance

  • DECLARATION interim analyses of antibody titers, pharmacokinetics, immunogenicity and safety were planned for Q4 2026; positive results could support a BLA under the accelerated approval pathway, with clinical events continuing as confirmatory data.

  • Initial FLINTLOCK data are expected in mid-2027; the Phase 2 trial evaluates high-dose VYD2311 in Long COVID or Post-Vaccination Syndrome.

  • VMS063 was expected to reach IND readiness in H2 2026, with clinical development anticipated in 2027; production scale-up is underway.

  • PEMGARDA’s EUA is set to terminate June 29, 2027; FDA discussions on next steps continue.

  • Expenses are expected to rise with clinical development, manufacturing and commercialization; funding may come from revenue, equity, grants, debt or partnerships.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Invivyd